Sildenafil in US Heart Failure Patients (SilHF-US)

Description

This protocol describes a 2-arm randomized controlled pilot study assessing the tolerance, safety and efficacy of sildenafil compared to control. The hypothesis is that sildenafil will be well tolerated and efficacious in patients with chronic heart failure (NYHA class II and III) with evidence of systolic dysfunction (EF ?40 %) and secondary pulmonary hypertension (SPAP >40mmHg). Patients that satisfy the inclusion criteria will be randomized to sildenafil (40mg x 3) or placebo therapy for 6 months in a 2:1 blinded fashion. The placebo group will be compared to the active therapy group and analyzed for differences in the main study end-points Patient Global Assessment and 6-Minute Walk Test. The study will also assess safety, tolerability, symptoms and quality of life.

Study Start Date

February, 14 2018

Estimated Completion Date

December 2018

Interventions

  • Drug: Sildenafil
  • Drug: Placebo oral capsule

Study ID

Hartford Hospital -- HHC-2016-0152

Status

Unknown

Trial ID

NCT03460470

Study Type

Interventional

Trial Phase

Phase 3

Enrollment Quota

25

Sponsor

Hartford Hospital

Inclusion Criteria

    1. Men and women 2. 18
  • 80 years of age. 3. Outpatients with chronic HF. NYHA class II-III on optimal treatment in sinus rhythm or atrial fibrillation 4. LVEF ? 40% measured during the past 12 months 5. SPAP ? 40mmHg using echocardiography 6. 6MWTD < 475 meters 7. NT-pro BNP ? 400 pg/ml or BNP ?100 pg/ml, measured during the past 12 months 8. Receiving optimal therapy, including diuretic, ACE-inhibitor, ARB, beta-blocker and aldosterone antagonist. Doses of all medication should be unchanged during the last 30 days before inclusion. 9. ICDs and CRTs (CRT-P, CRT-D) are permitted. Implantation should have been performed at > 3 months before inclusion to the trial.

Exclusion Criteria

    - 1. Acute Coronary Syndrome, including myocardial infarction, or coronary angiography, with or without intervention, within the last 3 months 2. Stroke within the last 3 months 3. Planned coronary angiography or planned device-implantation 4. Moderate to severe obstructive valve disease 5. Documented episodes of sustained ventricular tachycardia 6. Prior (past 30 days before the baseline visit) or ongoing use of oral nitrate therapy. 7. Concomitant disease which interfere with assessment of dyspnea , severe COPD, asthma, restrictive lung disease, severe obesity 8. Anemia (hemoglobin < 10g/dL) 9. Uncontrolled hypertension ( SBP >160 mmHg and / or DBP > 90 mmHg) 10. Symptomatic or orthostatic hypotension or systolic blood pressure < 90 mmHg 11. Clinically important renal dysfunction (GFR < 40m ml/min) 12. Women with child-bearing potential 13. Prior (past 30 days before the baseline visit) or ongoing use of i) alpha-1 antagonist: doxazosin ii) CYP3A4 inhibitors: erytromycin, ritonavir, sakinovir, itrakonazole, ketokonazole iii) CYP3A4-inducers: rifampicin iv) Any calcium channel blockers 14. V) Pulmonary vasodilators at the treatment dose level for Pulmonary hypertensionRetinitis pigmentosa, previous diagnosis of NAION (non-arteritic ischemic opticus-neuropathy), unexplained visual disturbance. 15. Sickle cell anemia, multiple myeloma, leukemia or penile anatomic deformities (angulation, cavernosal fibrosis, Peyronie`s disease) that increases the risk of priapism. 16. Hepatic failure. 17. Drug and alcohol abuse which precludes compliance with the protocol. 18. Inability to understand or sign the written informed consent form of the study,

Gender

All

Ages

18 Years to 80 Years

Accepts Healthy Volunteers

No

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Hartford Hospital 80 Seymour street - Hartford, Connecticut 48.4 miles Konstadina Darsaklis MD 860-972-1212 konstadina.darsaklis@hhchealth.org

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.